Considering your experience with Sharlife so far, how likely are you to recommend us to a friend or colleague?
Not at all likelyExtremely likely
(Optional)
Shanghai Pharmaceuticals Holding Co. Ltd. Class H
2607Health technology
$8.5B
Market Cap
Shariah Analysis
Failed
Business
Cash
Liabilities
Based on AAOIFI screening standards, Shanghai Pharmaceuticals Holding Co. Ltd. Class H appears to be Failed.
Business Activity
Revenue breakdown data currently unavailable.
Financial Screening
FYE 2024
Cash (<30%)107.56%
Non-Shariah Cash Items
Cash And Cash Equivalents$35.7B
Other Short Term Investments$8.6B
Hedging Assets Current$16.2M
Liabilities (<30%)115.79%
Non-Shariah Liabilities
Long Term Debt$8.3B
Long Term Capital Lease Obligation$1.4B
Current Debt$38.1B
Market Data
Exchange
HKEX
CurrencyUSD
CountryHong Kong
Last Updated2025-12-15
Disclaimer: Shariah screening is based on the latest available financial data. Market conditions and company activities may change. Always conduct your own due diligence.
HKEX
